At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 11 enrolled
Drug / intervention
MDGN201 TARGTEPObiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Sustained Erythropoietin Therapy of Anemia in Chronic Kidney Disease (CKD) Patients and End-Stage Renal Disease (ESRD) Dialysis Patients Using MDGN201 TARGTEPO
Aevi Genomic Medicine, LLC, a Cerecor company·interventional·Posted Apr 21, 2014·Updated Oct 30, 2018
In Brief
A Phase 2 clinical trial evaluating MDGN201 TARGTEPO for Chronic Kidney Disease and End Stage Renal Disease. Completed, enrolled 11 participants across 5 sites.
Detailed Summary
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease, End Stage Renal Disease
CountriesIsrael
CollaboratorsMedgenics Medical Israel Ltd.
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 2014
Enrollment StartMay 2014
Primary CompletionJun 2016
Study CompletionMar 2017
TodayJul 2026
First PostedApr 21, 2014
Enrollment StartMay 27, 2014
Primary CompletionJun 30, 2016
Study CompletionMar 20, 2017
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 12.2 years ago
Interventions
MDGN201 TARGTEPObiological
Erythropoietin secreted by TARGTEPO transduced with MDGN201